Member Info for maestro1

Those buys and sells are not always accurate..

Without doubt great product, will be volatile until the day traders leave.

Ce mark in 6 weeks so thats the next milestone.

So if its not to be this year then it shouldnt effect sp.

The canadian assets are still not fully priced into sp.
Q2 im confident production will increase..

Dave with the way budd did last placin he annoyed alot of pi's. Sp 160p and did placing at 80p.

Dhr i will take £4 for my shares now.. :)

Rizvi

I get all that, its fallen over 20%.

I may derisk some as 80% of my portfolio is here.

Come on gdr..

Rizvi

Thats my concern, all my gains are gone, if it goes further down im in negative territory.:(

So starting to do more research, last fjnancial year june 2020, the expenses were £7m, they had 8m in the bank, but end of oct 20 they had 5m in the bank.

So if no near terms sales a placing is possible. Now my concern is if he mentions the same they are still waiting for eua and india is progressing and no significant sales, pi's will tank the share.

A long think over weekend in two stocks only..

Frustrating... all my gains gone.

I still believe the aihl product alone justifies current mkt cap.

Last time nov results ther was no sales and sp fell.

Paul

Something is the back of my mind is telling me that we may not large contract until eua from fda. We get that i will be 100% confident.

Budd used that excuse in last results he cant use it again.

I will not follow him blindly, also want assurances there will not be placing at significant discount like last time.

Our pcr test on paper is the best and easiest to use, we should be selling loads. A large labaratory contract and we in the money.

Jayhayes

I bet they say they are still waiting fda and india is progressing. Remember in last set of results

"We remain confident in our SAR CoV-2 products and through our network of commercial and other partners we see significant commercial opportunities ahead although additional regulatory clearances are still awaited in certain key territories. "

So my question is since then what additional regulatory clearances have they made? It seems its still the same?

I will consider my position if no progress is made on this front. I like the company buts its been nearly a year...

Dave

Been following this company for long time, it has potential but its time consuming, fda will not issue license this year, i guarantee that.

Now they need to look for distributor in uk and europe.

Wait for daytraders to leave and let it settle, gonna take 6 weeks to get CE mark.

Dont get spiked, ii's hav an habit to dump this stock.

Around 6 weeks to get the CE licence, so still some time. Let it settle and day traders leave then pounce..

The mkt didnt take notice how how we managed to bag a large distributor for pathogen test. It validates the product and opens up more opportunities. Now we likely to sell to other departments in military.

Ask yourself who may have recommended mountain horse to us?

Thats the spirit.

Some contracts by 22nd march in usa, might have beckmans name on it.

Dont want to be out over the weekend. :)

Contract signed anyday now. "Its kickoff time"

Fairly confident it will happen, majority of growth will occur q2.

Can see the rns state:

Commercial partner for dod contract signed
Commercial partner pcr test signed
Debt free this year
Aihl study complete, launching in summer, distributor signed.
Poc covid test release

All this for 80m mkt cap

When lft is done and you are positive they still make you do pcr test.

Covid is here to stay for awhile, flying in and out of country will require pcr test. Beckman just need the contracts which im sure they will get.

Waiting game..

Rizvi

Now covid relief bill signed they can issue contracts at anytime. GDR are alot further now than they were 6 months ago. The mkt should be alot interested now than before.

The launch of the genedrive AIHL assay remains on track for summer 2021 and the Company is enthusiastic about both the commercial prospects and the clinical benefits of this novel test to prevent potential irreversible hearing loss and this test becoming a standard of care. The Company is executing initial stage key opinion leader engagement in the UK alongside Inspriration Healthcare in preparation for commercial launch.

genedrive's assay is the only commercial point of care test available for the testing of MT-RNR1, the most important mutation contributing to AIHL in infants.